Researchers link statin-related muscle injury to a calcium leak
Scientists at the University of British Columbia and the University of Wisconsin–Madison have identified a molecular mechanism that may explain why statins can sometimes cause muscle pain, weakness and, in rare cases, severe muscle damage. Their findings, reported in Nature Communications, point to an interaction between statin molecules and a protein channel that controls calcium movement inside muscle cells.
Statins are widely used cholesterol-lowering medicines that help reduce the risk of heart attacks and strokes. Their cardiovascular benefit is substantial, but some patients experience muscle-related side effects. The new work does not challenge the role of statins in preventing cardiovascular disease. Instead, it provides a proposed explanation for how an unwanted effect can arise in muscle tissue and could help guide efforts to develop medicines with fewer such effects.
The research centers on the ryanodine receptor 1, or RyR1, a protein that regulates calcium release in muscle cells. Under normal conditions, the channel opens in a controlled way when calcium is needed for muscle contraction. The researchers found that statins can bind to this channel and hold it open, allowing calcium to leak continuously into areas where its levels are normally tightly controlled.
Why calcium control matters in muscle
Calcium is essential to muscle function. Muscle cells use carefully timed calcium release to initiate contraction, then restore calcium balance afterward. A channel that remains open can disrupt that balance. The researchers say the resulting continuous leak creates conditions that can injure muscle tissue and offers an explanation for symptoms ranging from muscle discomfort to more serious complications.
The study used cryo-electron microscopy, a method that enables researchers to examine protein structures in high detail. By visualizing how statin molecules interact with RyR1, the team was able to identify a direct molecular route through which the medicines may affect muscle cells.
Lead author Steven Molinarolo, a postdoctoral researcher in UBC’s department of biochemistry and molecular biology, said the team could see how statins attach to the channel. The work connects that physical interaction to a functional consequence: a calcium channel that is held open rather than operating as a controlled gateway.
An explanation for a known clinical problem
Muscle symptoms associated with statins have long been recognized, even though the medicines remain among the most important tools for lowering cholesterol and preventing cardiovascular events. For some people, symptoms may include pain or weakness. A small number of patients can develop severe muscle breakdown, a complication that can potentially lead to kidney failure.
The newly described mechanism gives researchers a specific target for investigating why those effects occur and how they might be prevented. It also reframes the problem at the molecular level: rather than treating muscle symptoms as a general or poorly defined reaction, scientists can examine how individual compounds interact with a key calcium-control protein.
The source material describes the finding as one that could open the door to safer cholesterol medicines. That possibility remains prospective. A structural and mechanistic finding is an important foundation, but translating it into a new drug or a modified statin will require additional research, drug-design work and clinical testing.
What the result could mean for drug design
A medication can be highly effective at its intended job while still producing side effects through interactions elsewhere in the body. The study suggests that, for statin-associated muscle injury, a relevant off-target interaction may be the binding of statins to RyR1. If scientists can preserve cholesterol-lowering activity while reducing or avoiding that interaction, they may be able to design treatments with a lower risk of muscle toxicity.
The work may also help researchers compare different statin molecules more precisely. The source describes examination of three statin molecules, alongside structural imaging of their relationship to the calcium channel. Future studies can build on that approach to assess whether particular chemical features affect the channel differently and whether those differences correspond to muscle effects.
That is especially relevant because patients do not all respond to medicines in the same way. A molecular mechanism can create a starting point for research into why susceptibility varies, though the supplied report does not establish which patients are more likely to experience symptoms or recommend changes to clinical treatment.
Patients should not alter treatment based on this study alone
The research helps explain a side effect; it is not a reason for patients to stop prescribed statins without medical guidance. Statins help prevent heart attacks and strokes, and any decision about medication should weigh the known cardiovascular benefits against individual symptoms and risks. Patients experiencing muscle pain or weakness should discuss it with their clinician, who can assess possible causes and determine an appropriate next step.
For researchers, the advance is the visibility of a specific interaction that had not previously been resolved at this level of detail. Cryo-electron microscopy allowed the team to observe the binding event almost atom by atom, linking a structural observation to calcium dysregulation in muscle cells.
For drug development, the significance lies in the possibility of separating desired and undesired effects. The aim would not be to abandon a drug class that has prevented cardiovascular disease for millions of people, but to understand and minimize the molecular pathway that can harm muscle tissue in a subset of patients.
A clearer target for the next stage of research
The study provides a testable mechanism for statin-associated muscle damage: binding to RyR1 can force open a channel that normally regulates calcium flow, leading to a persistent calcium leak. The next scientific challenge is to use that insight to develop and evaluate safer treatments while retaining the cholesterol-lowering benefits that make statins so important.
That work will require further laboratory investigation and, ultimately, clinical evidence. But by identifying a specific protein interaction behind a long-recognized side effect, the researchers have moved the question from observation toward mechanism—and given future drug-design efforts a more defined place to start.
This article is based on reporting by Science Daily. Read the original article.
Originally published on sciencedaily.com
